Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 1, 2013, Pages 25-38

  Jiang, Jingwei ^a,b   Liang, Xiaohua ^a,b   Zhou, Xinli ^a,b   Huang, Ruofan ^a,b   Chu, Zhaohui ^a,b   Zhan, Qiong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Carcinoma; Chemotherapy; Meta analysis; Non small cell lung; Platinum; Third generation agents

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HEARING IMPAIRMENT; HUMAN; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; ODDS RATIO; PACLITAXEL; PLATINUM COMPOUNDS; PUBLICATION BIAS; RESEARCH REPORT; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84872288602     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1294-z     Document Type: Article

References (41)

1. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847-857
2. Azzoli CG, Baker SJ, Temin S, Pao W, Aliff T, Brahmer J et al (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266
3. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2:845-853
4. Barata FJ, Parente B, Cunha J, Fernandes A, Figueiredo A, Conde S et al (2002) A phase II study, multicenter, randomized of carboplatin plus gemcitabine (CG) versus vinorelbine plus gemcitabine (VG) in advanced non small cell lung cancer (NSCLC) [abstract]. ESMO annual meeting. 523 p
5. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101
6. Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM et al (2002) Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 13:108-115
7. Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63-70
8. D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926-2936
9. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):S116-S119
10. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634
11. Fløtten Ø, Bremnes RM, Grønberg BH, Sundstrøm S, Amundsen T, Rolke H et al (2010) Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: a Norwegian Lung Cancer Study Group trial [abstract]. J Clin Oncol 15(suppl): abstr 7597
12. Galvez C, Galmarini F (2000) Gemcitabine/cisplatin (G/P) vs gemcitabine/vinorelbine (G/V) in the treatment of non-small cell lung cancer (NSCLC): stage IIIB and IV abstract]. Ann Oncol 11(suppl 4):S115 (abstr 526P)
13. Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results [abstract]. ASCO Annual Meeting Proceedings Part I 24(18S): abstr 17116
14. Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A et al (2001a) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47-S51
15. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M et al (2001b) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478-1484
16. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937-2945
17. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025-3034
18. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G et al (2009) Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14:497-510
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557-560
20. Iwamoto Y, Saito H, Nakagawa K, Kashii T, Katakami N, Nakano T, et al (2007) A randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group 00 [abstract]. ASCO Annual Meeting Proceedings Part I 25(18S): abstr 18060
21. Jahnke K, Keilholz U, Luftner D, Thiel E, Schmittel A (2011) Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer. Anticancer Res 31:317-323
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
23. Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348-358
24. Julian PTH, Douglas GA, Jonathan ACS (updated March 2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0. http://www.cochrane-handbook.org. Accessed 10 Feb 2012
25. Katakami N, Takiguchi Y, Yoshimori K, Isobe H, Bessho A, Yoshimura A et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 1:447-453
26. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578-3585
27. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D et al (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115-122
28. Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M et al (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97-101
29. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
30. Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology 17:357-364
31. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834
32. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602-610
33. Rigas JR, Carey M, Dragnev KH, Simeone SA, Page RD, Rubin MS et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): subgroup analysis from D0112 [abstract]. J Clin Oncol 26(15suppl): abstr 8100
34. Rubio JC, Vazquez S, Vazquez F, Amenedo M, Fírvida JL, Mel JR et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379-384
35. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909-3917
36. Solomon B, Bunn PA Jr (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31:571-576
37. Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K et al (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 15:1048-1055
38. Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K et al (2005) Randomized study of vinorelbine-gemcitabine versus vinorelbine- carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49:233-240
39. Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM et al (2010) A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 21:540-547
40. Walling J (1994) Chemotherapy for advanced non-small-cell lung cancer. Respir Med 88(649-657):18
41. Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S et al (2006) West Japan Thoracic Oncology Group (WJTOG). Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107:599-605